Alexion Pharm Inc (ALXN) Fundamental Analysis & Valuation

NASDAQ:ALXN

Current stock price

182.5
+3.05 (+1.7%)
At close:
183
+0.5 (+0.27%)
After Hours:

This ALXN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ALXN Profitability Analysis

1.1 Basic Checks

  • ALXN had positive earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA 3.66%
ROE 5.48%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM 9.15%
PM (TTM) 10.89%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. ALXN Health Analysis

2.1 Basic Checks

  • ALXN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

  • ALXN has an Altman-Z score of 5.06. This indicates that ALXN is financially healthy and has little risk of bankruptcy at the moment.
  • A Debt/Equity ratio of 0.19 indicates that ALXN is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 5.06
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

  • ALXN has a Current Ratio of 4.52. This indicates that ALXN is financially healthy and has no problem in meeting its short term obligations.
  • ALXN has a Quick Ratio of 3.96. This indicates that ALXN is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.52
Quick Ratio 3.96

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. ALXN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 12.94% over the past year.
  • Measured over the past years, ALXN shows a very strong growth in Earnings Per Share. The EPS has been growing by 20.12% on average per year.
  • The Revenue has grown by 18.24% in the past year. This is quite good.
  • Measured over the past years, ALXN shows a quite strong growth in Revenue. The Revenue has been growing by 18.44% on average per year.
EPS 1Y (TTM)12.94%
EPS 3Y28.83%
EPS 5Y20.12%
EPS Q2Q%9.32%
Revenue 1Y (TTM)18.24%
Revenue growth 3Y19.57%
Revenue growth 5Y18.44%
Sales Q2Q%13.27%

3.2 Future

  • Based on estimates for the next years, ALXN will show a small growth in Earnings Per Share. The EPS will grow by 6.32% on average per year.
  • ALXN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.94% yearly.
EPS Next Y9.86%
EPS Next 2Y8.02%
EPS Next 3Y8.65%
EPS Next 5Y6.32%
Revenue Next Year12.08%
Revenue Next 2Y9.81%
Revenue Next 3Y8.89%
Revenue Next 5Y7.94%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ALXN Yearly Revenue VS EstimatesALXN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B
ALXN Yearly EPS VS EstimatesALXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

2

4. ALXN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 14.22, which indicates a correct valuation of ALXN.
  • ALXN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.18.
  • ALXN is valuated correctly with a Price/Forward Earnings ratio of 12.48.
  • The average S&P500 Price/Forward Earnings ratio is at 37.96. ALXN is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 14.22
Fwd PE 12.48
ALXN Price Earnings VS Forward Price EarningsALXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.39
ALXN Per share dataALXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.44
PEG (5Y)0.71
EPS Next 2Y8.02%
EPS Next 3Y8.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALXN Dividend Analysis

5.1 Amount

  • ALXN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ALXN Fundamentals: All Metrics, Ratios and Statistics

Alexion Pharm Inc

NASDAQ:ALXN (7/20/2021, 9:56:13 PM)

After market: 183 +0.5 (+0.27%)

182.5

+3.05 (+1.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)02-22
Inst Owners0%
Inst Owner Change0%
Ins Owners0.8%
Ins Owner Change0%
Market Cap40.34B
Revenue(TTM)6.26B
Net Income(TTM)681.80M
Analysts66.2
Price Target180.9 (-0.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 14.22
Fwd PE 12.48
P/S 6.44
P/FCF N/A
P/OCF N/A
P/B 3.24
P/tB N/A
EV/EBITDA 13.39
EPS(TTM)12.83
EY7.03%
EPS(NY)14.62
Fwd EY8.01%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS28.33
BVpS56.24
TBVpSN/A
PEG (NY)1.44
PEG (5Y)0.71
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 3.66%
ROE 5.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 9.15%
PM (TTM) 10.89%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.52
Quick Ratio 3.96
Altman-Z 5.06
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.94%
EPS 3Y28.83%
EPS 5Y20.12%
EPS Q2Q%9.32%
EPS Next Y9.86%
EPS Next 2Y8.02%
EPS Next 3Y8.65%
EPS Next 5Y6.32%
Revenue 1Y (TTM)18.24%
Revenue growth 3Y19.57%
Revenue growth 5Y18.44%
Sales Q2Q%13.27%
Revenue Next Year12.08%
Revenue Next 2Y9.81%
Revenue Next 3Y8.89%
Revenue Next 5Y7.94%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Alexion Pharm Inc / ALXN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for Alexion Pharm Inc?

ChartMill assigns a fundamental rating of 5 / 10 to ALXN.


What is the valuation status for ALXN stock?

ChartMill assigns a valuation rating of 3 / 10 to Alexion Pharm Inc (ALXN). This can be considered as Overvalued.


How profitable is Alexion Pharm Inc (ALXN) stock?

Alexion Pharm Inc (ALXN) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for ALXN stock?

The Price/Earnings (PE) ratio for Alexion Pharm Inc (ALXN) is 14.22 and the Price/Book (PB) ratio is 3.24.


What is the earnings growth outlook for Alexion Pharm Inc?

The Earnings per Share (EPS) of Alexion Pharm Inc (ALXN) is expected to grow by 9.86% in the next year.